Rapport Therapeutics, Inc. Payments of Stock Issuance Costs
Rapport Therapeutics, Inc. (RAPP) reported Payments of Stock Issuance Costs of $58.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2024-08-08.
Financial Statements › Statement of Cash Flows › Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation › Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation › Cash Provided by (Used in) Financing Activity, Including Discontinued Operation › Cash Provided by (Used in) Financing Activity, Continuing Operation › Payment of Financing and Stock Issuance Costs
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-08-08
- 2023-06-30: Payments of Stock Issuance Costs 6 month $58.00K.
| Period end | Payments of Stock Issuance Costs 6 month |
|---|---|
| 2023-06-30 | $58.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |